Pfizer Raises 2026 Outlook on Eliquis Surge but Patent Cliff Looms Large
Submitted by Anonymous (not verified) on Fri, 08/14/2026 - 16:02Pfizer delivered another quarter of solid commercial execution. On August 4 the drugmaker posted second-quarter revenue of $15.03 billion. That topped Wall Street forecasts by a healthy margin. Adjusted earnings per share came in at 77 cents, beating expectations of 68 cents. Yet the headline number that moved markets was the decision to lift the low end of full-year 2026 revenue guidance.